⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers

Kathryn Gunn Matti Myllykoski John Z. Cao Manna Ahmed Bofu Huang Betty Rouaisnel Bill H. Diplas Michael M. Levitt Ryan Looper John G. Doench Keith L. Ligon Harley I. Kornblum Samuel K. McBrayer Hai Yan Cihangir Duy Lucy A. Godley Peppi Koivunen Julie-Aurore Losman

View Full Paper

Ask AI

Bookmark

Share

Abstract

Inhibition of KDM5 enzymes by the (R)- and (S)-enantiomers of 2-hydroxyglutarate.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gunn et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875234cc https://doi.org/10.1158/2159-8290.27025184

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
2Supplementary Figure S5 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
3Supplementary Figure S5 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
4Supplementary Figure S7 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024
5Supplementary Figure S7 from (R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers2024